Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980805 | 0.97 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTCYP1A2KDM4ENPC1 | |
| SCHEMBL14756184 | 0.83 | CHRM2 (0.63) | SMN1; SMN2CYP1A2KDM4ENPC1LMNA | |
| SCHEMBL8090972 | 0.82 | SIGMAR1 (0.57) | CYP1A2CYP2A6SIGMAR1 | |
| SCHEMBL254573 | 0.82 | SMN1; SMN2 (0.72) | SMN1; SMN2HTTKDM4ELMNAMAPT | |
| SCHEMBL10087661 | 0.80 | CHRM2 (0.68) | SLC2A1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL15981454 | 0.80 | LMNA (0.49) | SMN1; SMN2HTTCYP1A2KDM4ELMNA | |
| SCHEMBL9492873 | 0.79 | MTNR1A (0.62) | SMN1; SMN2CYP1A2KDM4ENPC1LMNA | |
| SCHEMBL15980808 | 0.79 | HPGDS (0.44) | SMN1; SMN2HTTSLC6A2SLC6A3SLC2A1 | |
| SCHEMBL9667596 | 0.79 | CHRM2 (0.67) | SMN1; SMN2CYP1A2KDM4ENPC1LMNA | |
| Hydrochloric Acid SCHEMBL11279316 | 0.78 | LMNA (0.50) | SMN1; SMN2HTTCYP1A2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | SMN1; SMN2 4253/4885HTT 2844/4885CYP1A2 4686/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | SMN1; SMN2 3490/4885HTT 2677/4885CYP1A2 4875/4885 |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | SMN1; SMN2 4140/4885HTT 2932/4885CYP1A2 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.